NDRA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-14

• As used in this Quarterly Report on Form 10-Q (this “Form 10-Q”), unless the context otherwise requires, the terms “we,” “us,” “our,” “ENDRA” and the “Company” refer to ENDRA Life Sciences Inc., a Delaware corporation, and its direct and indirect subsidiaries. The following discussion and analysis o…

• On June 25, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ASP Isotopes Inc. (“ASP Isotopes”), a Delaware corporation, Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ASP Isotopes (“Noble”), Renerg…

• Concurrently with the entry into the Merger Agreement, Noble entered into subscription agreements (“Subscription Agreements”) with ASP Isotopes and certain investors pursuant to which Noble agreed to sell approximately (i) 4,594,218 Class A Units of Noble and/or pre-funded warrants to purchase Class…

• Additionally, prior to the effective time of the Merger (the “Effective Time”), ASP Isotopes will contribute all of its equity interest in Renergen to Noble in exchange for 55,500,000 of Noble’s Class B Units (the “Contribution”). The shares of Class B Common Stock (as defined below) received by ASP…

• Subject to the terms and conditions of the Merger Agreement, at the Effective Time, all of the units of Merger Sub outstanding immediately prior to the Effective Time shall be converted into and become units of the Surviving Company (“Surviving Company Units”) and ENDRA shall be admitted as the sole…

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• As used in this Quarterly Report on Form 10-Q (this “Form 10-Q”), unless the context otherwise requires, the terms “we,” “us,” “our,” “ENDRA” and the “Company” refer to ENDRA Life Sciences Inc., a Delaware corporation, and its direct and indirect subsidiaries. The following discussion and analysis o…

• No revenue has been generated by our TAEUS technology, which we have not commercially sold as of March 31, 2026.

• Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are de…

• We are experiencing financial and operating challenges. Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. As of March 31, 2026, we had an accumulated deficit of $111,776,942 and had $356,462 in cash. To date we have funded our operations thro…

• If we are unable to obtain adequate financing or financings in the near term or if the strategic alternatives review process does not result in any transaction or other strategic outcome, we will be forced to undertake additional measures, which may include materially curtailing or eliminating our o…

Text added vs the prior filing · source: 10-Q · 2026-08-14

• The Merger is subject to conditions, including approval by ENDRA’s stockholders, that are outside the Merger parties’ control, and the Merger may not be completed.

• The completion of the Merger is subject to the satisfaction or waiver of a number of conditions, many of which are outside the control of the parties. These conditions include, among others, the approval of the Merger and certain related proposals (the “ENDRA Stockholder Matters”) by our stockholder…

• Failure to complete the Merger could adversely affect the Company and the market price of our common stock.

• If the Merger is not completed, our business may be adversely affected subject to a number of risks, including that the market price of our common stock may decline to the extent that the current market price reflects an assumption that the Merger will be completed, that the parties will have incurr…

• Pursuant to the Side Letter Agreement, if the Merger is not consummated due to any decision of the Company not to continue pursuing the Merger, the Company is obligated to pay an amount equal to the 2026 Private Placement Purchase Price less the fair market value of the shares of common stock and/or…